Summary of the National Advisory Committee on Immunization’s Statement on the re-immunization with polysaccharide 23-valent pneumococcal vaccine

類似資料

• Statement on the Use of Conjugate Pneumococcal Vaccine – 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS)National Advisory Committee on Immunization (NACI)(*)
  著者:: Quach-Thanh, C., 等
  出版事項: (2013)
• Update on the Use of Conjugate Pneumococcal Vaccines in Childhood: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)(†)
  著者:: Desai, Shalini, 等
  出版事項: (2010)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  著者:: Tomczyk, Sara, 等
  出版事項: (2014)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
  著者:: Matanock, Almea, 等
  出版事項: (2019)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  著者:: Bennett, Nancy M., 等
  出版事項: (2013)